Synlogic, Inc. Board of Directors

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Ms. Mary Beth Dooley

Ms. Mary Beth Dooley

VP, Head of Finance and Principal Financial Officer & Principal Accounting Officer

Dr. James J. Collins Ph.D.

Dr. James J. Collins Ph.D.

Co-Founder & Member of Scientific Advisory Board

Dr. Timothy K. Lu M.D., Ph.D.

Dr. Timothy K. Lu M.D., Ph.D.

Co-Founder & Member of Scientific Advisory Board

Mr. Ajay Munshi

Mr. Ajay Munshi

Vice President of Corporate Development

Mr. Antoine Awad

Mr. Antoine Awad

Principal Executive Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.